|
GIPS-2
Glucose-Insulin-Potassium Study – 2
Ongoing trial
 |
Author(s) |
van der Horst ICC, Timmer JR, Ottervanger JP, Bilo HJG, Gans ROB, de Boer M-J, Zijlstra F |
 |
Title(s) |
Glucose-insulin-potassium and reperfusion in acute myocardial infarction: Rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2) |
|
Reference(s) |
Am Heart J 2005;149:585–91 |
|
Disease |
AMI |
|
Purpose |
To examine the effects of glucose-insulin-potassium (GIK) infusion as an adjunct to reperfusion therapy in patients with AMI |
|
Study design |
Randomised, open |
|
Follow-up |
Aim 30 days and 1 year |
|
Patients |
Aim 1044 patients with AMI, eligible for thrombolysis or primary percutaneous coronary intervention and without signs of heart failure |
|
Treatment regimen |
GIK infusion (glucose 20 %, short-acting insulin ≥ 5 U/h, KCl 40 mmol), 2 ml/kg/h for 12 h, or no GIK infusion |
|
Concomitant therapy |
Thrombolysis or primary percutaneous coronary intervention at the discretion of the physician |
|
Results |
Not yet available |
|
|
|
